Malignant hepatic tumors: Safety of high-dose percutaneous ethanol ablation therapy

Richard D. Redvanly, Judith L. Chezmar, Robert M. Strauss, John R. Galloway, Thomas D. Boyer, Michael E. Bernardino

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


The authors retrospectively analyzed clinical records to determine the safety and complication rate of percutaneous ethanol ablation therapy with more than 10 mL of ethanol administered per session for treatment of malignant hepatic tumors. Ten patients underwent a total of 35 sessions with 10 mL or more of ethanol, and four underwent 18 sessions with 10 mL or less. No serious complications occurred with any dose. Pain and fever were the most common complications at all doses, and the higher frequency of these at larger ethanol volumes may be related to the greater degree of tumor necrosis induced by the larger volume.

Original languageEnglish (US)
Pages (from-to)283-285
Number of pages3
Issue number1
StatePublished - Jul 1993
Externally publishedYes


  • Alcohol, 761.1269
  • Liver neoplasms, therapy, 761.1269, 761.323
  • Liver, interventional procedures, 761.1269

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Malignant hepatic tumors: Safety of high-dose percutaneous ethanol ablation therapy'. Together they form a unique fingerprint.

Cite this